A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease

A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects

NCT01853852 ·Status: COMPLETED ·Phase: PHASE1

Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study

NCT00526071 ·Status: TERMINATED ·Phase: PHASE2

A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

NCT00283959 ·Status: COMPLETED ·Phase: PHASE2

A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease

NCT00304512 ·Status: COMPLETED ·Phase: PHASE2

A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.

NCT00233870 ·Status: COMPLETED

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

NCT00074971 ·Status: COMPLETED ·Phase: PHASE3

German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl.

NCT03135197 ·Status: COMPLETED

A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease

NCT00140621 ·Status: COMPLETED ·Phase: PHASE4

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

NCT04049760 ·Status: COMPLETED ·Phase: PHASE3

Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease

NCT02194985 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

NCT03737214 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease

NCT06114329 ·Status: RECRUITING ·Phase: PHASE2

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy

NCT00973011 ·Status: COMPLETED ·Phase: PHASE1

Open-Label Phase 3 Long-Term Safety Study of Migalastat

NCT01458119 ·Status: TERMINATED ·Phase: PHASE3

Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

NCT03566017 ·Status: COMPLETED ·Phase: PHASE3

Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease

NCT02228460 ·Status: COMPLETED ·Phase: PHASE2

China Post-marketing Surveillance (PMS) Study of Fabrazyme®

NCT05054387 ·Status: COMPLETED ·Phase: PHASE4

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

NCT00081497 ·Status: COMPLETED ·Phase: PHASE4

Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease

NCT05710692 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Extension Study of PRX-102 for up to 60 Months

NCT01981720 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

NCT00925301 ·Status: COMPLETED ·Phase: PHASE3

An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease

NCT04519749 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

NCT06328608 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease

NCT06539624 ·Status: RECRUITING ·Phase: NA

A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease

NCT00074984 ·Status: COMPLETED ·Phase: PHASE4